Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients

Contributions to Nephrology

Volumn 147, Issue , 2005, Pages 149-160

  Bellinghieri, Guido ^a   Santoro, Domenico ^a,b   Savica, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b C da Conte Coop Sperone Is3/E   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; CHRONIC DISEASE; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; REVIEW; TUMOR LYSIS SYNDROME;

ACUTE DISEASE; CHRONIC DISEASE; HUMANS; HYPERURICEMIA; KIDNEY DISEASES; TUMOR LYSIS SYNDROME;

EID: 16644401486     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (41)

1. Sorensen LB, Levinson DJ: Origin and extrarenal elimination of uric acid in man. Nephron 1975;14:7-20.
2. Roch-Ramel F, Guisan B, Diezi J: Effect of uricosuric agents on urate transport in human transport brush-border membrane vesicles. J Pharmacol Exp Ther 1997;280:839-845.
3. Lieber CS, Jones DP, Losowsky MS, Davidson CS: Interrelation of uric acid and ethanol metabolism in man. J Clin Invest 1962;41:1863-1870.
4. Maclachlan MJ, Rodnan GP: Effect of food fast and alcohol on serum uric acid and acute attacks of gout. Am J Med 1967;42:38-57.
5. Saggiani F, Pilati S, Targher G, Branzi P, Muggeo M, Bonora E: Serum uric acid and related factors in 500 hospitalized subjects. Metabolism 1996;45:1557-1561.
6. Culleton BF: Uric acid and cardiovascular disease: A renal-cardiac relationship? Curr Opin Nephrol Hypertens 2001;10:371-375.
7. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-464.
8. Hatch M, Vaziri ND: Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci (Lond) 1994;86:511-516.
9. Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995;6(4):1313-1317.
10. Cohen AH, Nast CC: Kidney. Non-neoplastic conditions; in Damjanov I, Linder J (eds): Anderson's Pathology, ed 10. St Louis, Mosby-Year Book Inc., 1996, pp 2073-2137.
11. Bishop MR, Coccia PF: Tumor lysis syndrome; in Abeloff MD (ed): Clinical Oncology, ed 2. New York, Churchill Livingstone, 2000, pp 750-754.
12. Chasty RC, Liu-Yin JA: Acute tumor lysis syndrome. Br J Hosp Med 1933;49:488-492.
13. Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW: Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: A case report and review of the literature. Cancer 1999;85:1055-1059.
14. Fleming DR, Henslee-Downey PJ, Coffey CW: Radiation induced acute tumor lysis syndrome in the bone marrow transplant setting. Bone Marrow Transplant 1991;8:235-236.
15. Flombaum CD: Metabolic emergencies in the cancer patient. Semin Oncol 2000;27:332-334.
16. Sallan S: Management of acute tumor lysis syndrome. Semin Oncol 2001;28(suppl 5):9-12.
17. Conger JD, Falk SA, Guggenheim SJ, Burke TJ: A micropuncture study of early phase of acute urate nephropathy. J Clin Invest 1976;58:681-689.
18. De Conti RC, Calabresi P: Use of allopurinol for prevention and control of hyperuricemia in patient with neoplastic disease. N Engl J Med 1966;274:481-486.
19. Yeldandi AV, Yeldandi V, Kumar S, Murthy CV, Wang XD, Alvares K, Rao MS, Reddy JK: Molecular evolution of the urate oxidase-encoding gene in hominoid primates: Nonsense mutations. Gene 1991;109:281-284.
20. Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, Ribeiro RC, Sandlund JT, Rivera GK, Evans WE, Mahmoud HH: Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11:1813-1816.
21. Pui CH: Rasburicase: A potent urolytic agent. Expert Opin Pharmacother 2002;3:433-452.
22. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
23. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
24. Pui CH: Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experience. Semin Hematol 2001;38(suppl 10):13-21.
25. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-1190.
26. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, Harrison DG, Fukai T: Peroxidase properties of extracellular superoxide dismutase: Role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002;22:1402-1408.
27. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-1106.
28. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-2897.
29. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.
30. Mazzali M, Kim Y-G, Suga S, Gordon KL, Kang DH, Jeferson JA, Hughes J, Kivlighn SD, Lan HY, Johnson RJ: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001;71:900-905.
31. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 1997;51:1908-1919.
32. Cameron JS, Simmonds HA: Use and abuse of allopurinol. Br Med J 1987;294:1504-1505.
33. Rosenfeld JB: Effect of long term allopurinol administration on serial glomerular filtration rate in normotensive and hypertensive hyperuricemic subjects. Adv Exp Med Biol 1974;41:581-596.
34. Fessel WJ: Renal outcomes and gout and hyperuricemia. Am J Med 1982;72:95-100.
35. Johnson RJ, Kivlighn SD, Kim Y, Suga S, Fogo A: Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33:225-234.
36. Burnier M, Roch-Ramel F, Brunner HR: Renal effect of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787-1790.
37. Culletton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk of cardiovascular disease and mortality: The Framingham Health study. Ann Intern Med 1999;31:7-13.
38. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35:1025-1030.
39. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001;37:1069-1074.
40. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M: Serum uric acid and renal prognosis in IgA nephropathy. Nephron 2001;87:333-339.
41. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G: Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest 2001;31:318-321.